AMGN Stock Recent News

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again.

Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.

Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companies seem to have somewhat promising prospects in this field.

Amgen Inc. (NASDAQ:AMGN ) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ET Company Participants Justin Claeys - VP, IR Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Gregory Renza - RBC Capital Markets Gregory Renza Good morning everyone. Welcome back to 2025 RBC Global Healthcare Conference.

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent.

The stock of Amgen Inc.  AMGN is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend.